Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus

被引:0
作者
Yasuhiro Shimojima
Masayuki Matsuda
Takahisa Gono
Wataru Ishii
Shu-ichi Ikeda
机构
[1] Shinshu University School of Medicine,Third Department of Internal Medicine
来源
Clinical Rheumatology | 2005年 / 24卷
关键词
Autoantibody; Cerebrospinal fluid; Cytokine; Neuropsychiatric manifestation; Relapse; Systemic lupus erythematosus;
D O I
暂无
中图分类号
学科分类号
摘要
Neuropsychiatric symptoms are often seen in patients with systemic lupus erythematosus (SLE). To investigate the relationship between involvement of the nervous system and clinical factors, including autoantibodies and the activity of SLE, we retrospectively reviewed 25 patients with neuropsychiatric SLE (NPSLE, mean age: 35.2±12.2 years). As controls 37 SLE patients without neuropsychiatric manifestations (mean age: 31.8±15.8 years) were employed in this study. At the onset no significant differences were seen in any clinical factors between the patients and the controls except for serum antinuclear antibodies. In relapse, the patients with NPSLE showed significantly lower levels of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores without neuropsychiatric evaluation (p<0.0001), erythrocyte sedimentation rate (ESR, p<0.005), and antinuclear and anti-double-stranded DNA antibodies (p<0.005) and higher WBC values (p<0.05) than at the onset. Also in the patients with relapsing NPSLE similar significant differences were seen in these parameters between onset and relapse (p<0.005). Despite a lack of significant differences, the cerebrospinal fluid showed lower values in cell counts, total protein, and IgG in relapse than at onset. These results suggest that there are no clinical factors that predict the development of NPSLE and that relapse can occur with low disease activity in the nervous system even with an inactive state of other organ involvement. Since NPSLE may suddenly relapse with a slight change in common disease activation markers, including inflammatory reactions, autoantibodies, and complements in serum and CSF findings, adequate corticosteroid and/or immunosuppressive agents should be given at the onset and gradually be tapered after recovery, while looking out for recurrence.
引用
收藏
页码:469 / 475
页数:6
相关论文
共 122 条
[1]  
Ainiala H(2001)The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus Neurology 57 496-500
[2]  
Loukkola J(2001)Neuropsychiatric lupus Curr Rheumatol Rep 3 205-212
[3]  
Peltola J(1999)The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes Arthritis Rheum 42 599-608
[4]  
Korpela M(1992)Cognitive impairment in patients with systemic lupus erythematosus J Rheumatol 19 562-567
[5]  
Hietaharju A(2002)The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation Rheumatology (Oxford) 41 619-630
[6]  
Hanly JG(1990)Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement Arthritis Rheum 33 644-649
[7]  
Hanly JG(1994)Association of anti-Sm antibodies with organic brain syndrome secondary to systemic lupus erythematosus Lancet 343 796-94
[8]  
Fisk JD(1990)Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus Clin Rheumatol 9 82-1054
[9]  
Sherwood G(2002)Increased lymphocyte death by neglect-apoptosis is associated with lymphopenia and autoantibodies in lupus patients presenting with neuropsychiatric manifestations J Neurol 249 1048-1827
[10]  
Jones E(1998)Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus Arthritis Rheum 41 1819-1366